Dr. Alexandra Charrow presents insights from her presentation on managing challenging cases of hidradenitis suppurativa. She notes that clinicians often wait too long to initiate FDA-approved biologics and targeted therapies for their patients. Rather than relying solely on traditional staging, providers should consider targeted options after failed conservative treatments based on specific nodule, abscess, or sinus tract thresholds. Additionally, she encourages introducing early surgical procedures like deroofings alongside targeted medical therapy to best achieve patient remission.
